RESULTS
allergic asthmatic, SD, rhinitis, asthma, allergic symptoms
ADVERSE REACTIONS, RHINITIS, SECONDARY, ASTHMA, TSS
Data from 31 patients were available at the 10y‐FU visit (Table Demographic data and effectiveness results of the patients included in the observational study.At 10y‐FU compared with baseline.


The primary objective results showed a significant reduction in TSS (mean decrease [SD] −21.00 [16.56], Only those patients who received treatment for ≥3 years experienced a significant reduction in the MS at 10y‐FU compared with baseline (mean reduction [SD] −12.8 [16.9], A significant reduction in the number of patients with specific symptoms was observed between baseline and: (a) end of dpg‐pol HDM (i) for rhinitis (Reduction in the number of patients with allergic symptoms over time.Seventeen (54.8%) patients were asymptomatic at end of dpg‐pol HDM, of which 52.9% (9/17) remained asymptomatic at 10y‐FU (Figure Evolution of percentage of asymptomatic patients.Regarding the secondary objectives, VAS score at 10y‐FU visit assessed by patients was median 85 (range 75, 95), and likewise median 85 (range 80, 100) when assessed by investigator. No significant differences were observed between VAS at end of dpg‐pol HDM treatment compared with VAS at 10y‐FU. ACT showed a good control of asthma (ACT > 20) among allergic asthmatic patients at 10y‐FU; median 23.5 (range 22, 25) with no differences depending on dpg‐pol HDM treatment duration (Table No adverse reactions were reported during the study period.